SCHISTO_PERSIST SIGNED
New approaches to characterise Schistosoma mansoni infections persisting despite mass drug administration
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SCHISTO_PERSIST project word cloud
Explore the words cloud of the SCHISTO_PERSIST project. It provides you a very rough idea of what is the project "SCHISTO_PERSIST" about.
Project "SCHISTO_PERSIST" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITY OF GLASGOW
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 1˙490˙270 € |
| EC max contribution | 1˙490˙270 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2015-STG |
| Funding Scheme | ERC-STG |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-04-01 to 2022-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITY OF GLASGOW | UK (GLASGOW) | coordinator | 1˙490˙270.00 |
Map
Project objective
Neglected tropical diseases affect over 1.4 billion people and cause a greater disease burden than HIV/AIDS. Despite extensive mass drug administration (MDA) schistosomiasis remains a major public health issue, with a socio-economic impact second only to malaria amongst parasites. I will evaluate novel strategies and new technologies to monitor the impact of MDA programmes, to identify threats to MDA effectiveness, and enhance control of schistosomiasis in sub-Saharan Africa.
Specifically I will address five ambitious questions: 1. What is the best way to monitor schistosome infections and drug efficacy? 2. Has drug resistance been selected for? 3. What is the potential for drug resistance to spread? 4. What other factors drive transmission? 5. What other factors affect parasite clearance?
These aims are feasible through innovative interdisciplinary methods including a) state-of-the-art DNA-chip diagnostics, b) novel application of genetic analysis to differentiate surviving worms from juveniles, c) use of drug screening technology to measure in vitro drug susceptibility, providing the first quantifiable in vitro phenotype without using mammals, d) combination of molecular techniques with mathematical models to elucidate the potential spread of phenotypes and e) an unparalleled interdisciplinary approach deducing host effects in non-clearers.
These methods and technologies have not previously been used to assess MDA effectiveness for any helminth infection. My pioneering research will enable a comparative assessment of how transmission is affected by untreated adults and pre-school children, individuals with heavy infections, coinfections, and drug coverage. This will elucidate optimal strategies to reduce transmission hotspots.
My results will improve monitoring protocols and inform policy makers on how best to treat schistosomiasis. I will fill a critical global health knowledge gap, with findings transferable across a range of MDA controlled diseases.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Moses Adriko, Christina Faust, Lauren Carruthers, Arinaitwe Moses, Edridah Tukahebwa, Poppy Lamberton Low Praziquantel Treatment Coverage for Schistosoma mansoni in Mayuge District, Uganda, Due to the Absence of Treatment Opportunities, Rather Than Systematic Non-Compliance published pages: 111, ISSN: 2414-6366, DOI: 10.3390/tropicalmed3040111 |
Tropical Medicine and Infectious Disease 3/4 | 2019-08-30 |
| 2017 |
Poppy H.L. Lamberton, Christina L. Faust, Joanne P. Webster Praziquantel decreases fecundity in Schistosoma mansoni adult worms that survive treatment: evidence from a laboratory life-history trade-offs selection study published pages: 110, ISSN: 2049-9957, DOI: 10.1186/s40249-017-0324-0 |
Infectious Diseases of Poverty 6/1 | 2019-08-30 |
| 2018 |
JoaquÃn M. Prada, Panayiota Touloupou, Moses Adriko, Edridah M. Tukahebwa, Poppy H. L. Lamberton, T. Déirdre Hollingsworth Understanding the relationship between egg- and antigen-based diagnostics of Schistosoma mansoni infection pre- and post-treatment in Uganda published pages: , ISSN: 1756-3305, DOI: 10.1186/s13071-017-2580-z |
Parasites & Vectors 11/1 | 2019-08-30 |
| 2017 |
Mafalda Viana, Christina L. Faust, Daniel T. Haydon, Joanne P. Webster, Poppy H. L. Lamberton The effects of subcurative praziquantel treatment on life-history traits and trade-offs in drug-resistant Schistosoma mansoni published pages: , ISSN: 1752-4571, DOI: 10.1111/eva.12558 |
Evolutionary Applications | 2019-08-30 |
| 2018 |
JoaquÃn M. Prada, Panayiota Touloupou, Moses Adriko, Edridah M. Tukahebwa, Poppy H. L. Lamberton, T. Déirdre Hollingsworth Understanding the relationship between egg- and antigen-based diagnostics of Schistosoma mansoni infection pre- and post-treatment in Uganda published pages: , ISSN: 1756-3305, DOI: 10.1186/s13071-017-2580-z |
Parasites & Vectors 11/1 | 2019-08-30 |
| 2019 |
Stefanie Krauth, Julie Balen, Geoffrey Gobert, Poppy Lamberton A Call for Systems Epidemiology to Tackle the Complexity of Schistosomiasis, Its Control, and Its Elimination published pages: 21, ISSN: 2414-6366, DOI: 10.3390/tropicalmed4010021 |
Tropical Medicine and Infectious Disease 4/1 | 2019-08-30 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCHISTO_PERSIST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SCHISTO_PERSIST" are provided by the European Opendata Portal: CORDIS opendata.